pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
13h
CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
biospace
14h
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
14h
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
15h
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
15h
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
17h
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
19h
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
1d
AI drugmaker Isomorphic restocks with $5B fundraise
biopharma dive
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
biospace
2d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
2d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
3d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
3d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
5d
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
biospace
5d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
5d
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
biopharma dive
6d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
6d
Deep dive: Cardiovascular calamities and catalysts
biospace
6d
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
stat
6d
Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
biospace
6d
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
biopharma dive
6d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
6d
BMS R&D head to depart amid restructure
biospace
6d
Updated: Bristol Myers shakes up R&D leadership ahead of patent cliff
endpoints
6d
BMS reunites R&D divisions under Cristian Massacesi, while Robert Plenge departs
fiercebiotech
7d
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
endpoints
7d
Beeline reveals Phase 2 lupus data from old Bristol Myers drug
endpoints
7d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
8d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
← prev
page 1 of 12
next →